Beigene Ltd Company Profile (NASDAQ:BGNE)

Analyst Ratings

Consensus Ratings for Beigene Ltd (NASDAQ:BGNE) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.67 (45.30% upside)

Analysts' Ratings History for Beigene Ltd (NASDAQ:BGNE)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyBoost Price Target$39.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Robert W. BairdInitiated CoverageOutperform$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Goldman Sachs Group Inc.Initiated CoverageBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Beigene Ltd (NASDAQ:BGNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Beigene Ltd (NASDAQ:BGNE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Beigene Ltd (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Beigene Ltd (NASDAQ:BGNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Beigene Ltd (NASDAQ:BGNE)
DateHeadline
07/23/16 07:03 AMTop Gainers, Losers in Manufacturing Sector Today
07/05/16 03:41 PMBeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China - [at noodls] - WALTHAM, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment ...
07/03/16 07:33 AMProfile: BeiGene Ltd (BGNE.OQ)
07/01/16 07:59 PMHavre de Grace’s Independence Celebrations set for this weekend
07/01/16 07:59 PMBaltimore Hospital finds alternative medevac site
07/01/16 07:59 PMAll Food Will be Local For First Time in Artscape History
07/01/16 07:59 PMCelebrate Independence Day at the Inner Harbor
07/01/16 07:59 PMThe Arc Baltimore Names BGE's Larry Burley to its Board of Directors
07/01/16 07:59 PMBeigene Ltd (NASDAQ:BGNE) Doses First Patient In Combination Trial Of BGB-A317 and BGB-3111
07/01/16 07:59 PMBGE restores ospreys' home after a lighting strike destroys their nest
07/01/16 07:59 PMBGE Inks Medevac Helicopter Deal with Baltimore Hospital
07/01/16 07:59 PMBGE customers can join texting program for outages
06/29/16 03:51 PMBeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 - [at noodls] - WALTHAM, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, ...
06/14/16 03:44 PMU.S. regulator says too many drugmakers chasing same cancer strategy - [Reuters - UK Focus] - A new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S (Other OTC: UBGXF - news) . Dr. Richard Pazdur, head of the Food and Drug Administration's office of oncology products, was referring to therapies designed to disable the PD-1 protein that tumors use to evade the immune system. The FDA has approved such treatments from Merck (Jakarta: 28586808.JK - news) & Co , Bristol-Myers Squibb Co and Roche Holding AG (LSE: 0QOK.L - news) , each of which have list prices of $150,000 per year.
06/05/16 08:08 AMBeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting - [at noodls] - WALTHAM, Mass., June 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ...
05/19/16 05:52 AMBeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting - [at noodls] - WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ...
05/12/16 03:25 PMBEIGENE, LTD. Files SEC form 10-Q, Quarterly Report -
05/11/16 04:07 PMBeiGene Reports First Quarter 2016 Financial Results - [at noodls] - WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ...
05/04/16 04:41 PMBeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development - [at noodls] - WALTHAM, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs ...
04/28/16 07:03 AMChinese Commodities Brokerage Yintech Debuts on Nasdaq - Yintech is only the third Chinese company to list in the U.S. this year. In the first such IPO of 2016, immuno-oncology drug developer BeiGene Ltd. BGNE-4.65 % raised $182 million on Nasdaq in February. This was followed in March by the $110 million Nasdaq ...
04/21/16 08:30 AMOpening Bell, April 21, 2016 -
04/20/16 09:21 AMBeiGene (Nasdaq: BGNE) to Ring The Nasdaq Stock Market Opening Bell - [at noodls] - ADVISORY, April 20, 2016 (GLOBE NEWSWIRE) -- What: BeiGene (Nasdaq:BGNE), a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics will visit ...
04/19/16 08:26 AMBeiGene Ltd. :BGNE-US: Earnings Analysis: 2015 By the Numbers -
04/18/16 06:44 AMThe 11 year-old Dancing Trumps from Fiske Elementary School in Wellesley, Massachusetts were banned from entering the talent show - newratings.com berichtet: WASHINGTON - BeiGene Ltd 's (BGNE) initial data from an ongoing phase I clinical trial of BGB-283 in patients with BRAF or KRAS/NRAS-mutated cancers has demonstrated that treatment with single-agent BGB-283 is well tolerated with ...
04/18/16 06:40 AMBEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
04/17/16 04:26 PMBeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting - [at noodls] - WALTHAM, Mass., April 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs ...
04/11/16 04:10 PMBEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati -
04/11/16 04:00 PMBeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer - [GlobeNewswire] - WALTHAM, Mass., April 11, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today ...
04/05/16 12:04 PMBEIGENE, LTD. Financials -
04/04/16 03:45 PMWith Biotechnology Companies Leading the Way, Six Venture-Backed IPOs Recorded in First Quarter - In the largest IPO of the quarter, Beijing, China-based BeiGene Ltd (BGNE), raised $182.2 million and began trading on the NASDAQ stock exchange on February 2 nd. At the end of the first quarter, the company traded 22 percent above its $24 offering price.
03/31/16 06:23 AMEarnings Reported After The Bell Mar.30 - Analysts expected the company to report net income of $0.04 per share on revenues of $18.22 million for the period. BeiGene, Ltd. ( BGNE) Q4 net loss was $27.25 million or $3.05 per ADS vs. net loss of $3.74 million or $0.45 per ADS a year ago. Revenue was ...
03/30/16 03:24 PMBEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/30/16 03:05 PMBeiGene Reports Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - WALTHAM, Mass., March 30, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today ...
03/29/16 03:17 PMBEIGENE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers -
03/16/16 04:48 PMBeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting - [GlobeNewswire] - WALTHAM, Mass., March 16, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced ...
03/07/16 07:02 AM8:02 am BeiGene recieves clinical trial application approval from CFDA to conduct clinical trials with BGB-3111 -
03/07/16 07:00 AMBeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 - [GlobeNewswire] - BEIJING, March 07, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced ...
03/01/16 07:00 AMBeiGene to Present at Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - BEIJING, March 01, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced ...
02/29/16 02:33 PMMorgan Stanley: Buy BeiGene's Global Upside - Morgan Stanley’s Matthew Harrison initiated coverage of Beigene Ltd (ADR) (NASDAQ: BGNE) with an Overweight rating and a price target of $39, saying that China opportunity offers valuation support at around $25, while I/O combos offer upside in the ...
02/29/16 01:25 PMStreet Talk: CLR, HLT, BGNE, NFX & FET -
02/29/16 05:46 AMCoverage initiated on BeiGene by Robert W. Baird, Goldman and Morgan Stanley -
02/22/16 03:04 PM13D Filing: Baker Bros. Advisors and Beigene, Ltd. (BGNE) -
02/22/16 11:03 AM13D Filing: Billionaire Lei Zhang’s Hillhouse Capital Management Reports Stake in Beigene, Ltd. (BGNE) -
02/12/16 11:32 AMVolatile Market Flatlines Biotech IPOs -
02/12/16 07:04 AMNo Relief in Sight for IPO Market --Morning MoneyBeat -
02/12/16 05:23 AMOnly biotech companies have braved IPO market this year with a little insider help - Shares of Proteostasis were down as much as 30% from their IPO issue price of $8. Beigene Ltd. BGNE, -11.31% , the first IPO of 2016 and a drug company developing immuno-oncology drugs for cancer treatments, said in its prospectus that two existing ...
02/11/16 04:25 PMBEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, -
02/11/16 03:01 PMOnly biotech companies have braved IPO market this year — with insider help -
02/10/16 11:39 AMBill Gates’ Cascade Investment Boosts AutoNation Inc. (AN) Stake, Buffett Keeps Buying Phillips 66 (PSX), Plus Baker Bros.’ Latest Move -
02/09/16 10:04 AMLittle Hope For IPO Recovery In First Quarter -

Social

About Beigene Ltd

Beigene Ltd logoBeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BGNE
  • CUSIP:
Key Metrics:
  • Previous Close: $27.63
  • 50 Day Moving Average: $29.86
  • 200 Day Moving Average: $28.95
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $617.47M
  • Current Year EPS Consensus Estimate: $-3.17 EPS
  • Next Year EPS Consensus Estimate: $-3.24 EPS
Additional Links:
Beigene Ltd (NASDAQ:BGNE) Chart for Monday, July, 25, 2016